A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry

被引:11
作者
Bathum, L
Hansen, TS
Horder, M
Brosen, K
机构
[1] Odense Univ Hosp, Dept Clin Biochem, DK-5000 Odense C, Denmark
[2] Odense Univ, Dept Clin Pharmacol, DK-5230 Odense, Denmark
关键词
CYP2C19; genotyping; genetic polymorphism;
D O I
10.1097/00007691-199802000-00001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
CYP2C19 (S-mephenytoin hydroxylase) is a polymorphically expressed enzyme. Currently, two defective alleles are known-CYP2C19*2 and CYP2C19*3. The authors have developed an oligonucleotide ligation assay to detect these two alleles. This assay combines the hybridization of one common, biotinylated capture probe and two allele-specific probes to the target DNA, with the ability of a DNA ligase to distinguish mismatched nucleotides. The probes are only ligated if they are base paired correctly to the target strand. The biotin is bound to streptavidin, and all DNA not covalently bound to the biotin-labeled capture probe, is removed in a washing procedure. The allele-specific probes are labeled with either europium or samarium, and their emission can be measured simultaneously. The ratio between the emission separates the genotypes. This method was applied on DNA from 19 whites and 21 Vietnamese living in Denmark. All genotypes determined by the assay were consistent with the results from restriction enzyme cleavage. There were 12 poor metabolizers; 10 homozygous CYP2C19*2/CYP2C19*2, one heterozygous CYP2C19*2/CYP2C19*3, and one heterozygous CYP2C19*1/CYP2C19*2. The authors conclude that this assay is well-suited for a high throughput of samples in a routine laboratory. The finding of an apparently heterozygous CYP2C19*1/CYP2C19*2 poor metabolizer, confirms that there are still unknown mutations in CYP2C19.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [41] Association of CYP2C19*2 and*17 genetic variants with hypertension in Pakistani population
    Riaz, Sana
    Mansoor, Atika
    Siddiqi, Saima
    Tareen, Muhammad Usman
    Rubab, Sana
    Batool, Ayesha
    Anwarullah
    Sultan, Aneesa
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2019, 18 (04) : 851 - 855
  • [42] Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips
    Nakamoto, Kaori
    Kidd, Judith R.
    Jenison, Robert D.
    Klaassen, Curtis D.
    Wan, Yu-Jui Yvonne
    Kidd, Kenneth K.
    Zhong, Xiao-bo
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (02) : 103 - 114
  • [43] Physiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19
    Park, Hye-Jung
    Lee, Sang-Ho
    Kang, Pureum
    Cho, Chang-Keun
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    Bae, Jung-Woo
    Choi, Chang-Ik
    ARCHIVES OF PHARMACAL RESEARCH, 2025, : 234 - 250
  • [44] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
    Cho, Chang-Keun
    Byeon, Ji-Young
    Kang, Pureum
    Park, Hye-Jung
    Ko, Eunvin
    Mu, Chou Yen
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    ARCHIVES OF PHARMACAL RESEARCH, 2023, 46 (02) : 111 - 116
  • [45] Correlation between omeprazole hydroxylase and CYP2C19 genotype in North Indians
    Lamba, JK
    Dhiman, RK
    Singh, R
    Kohli, KK
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (09) : 649 - 652
  • [46] CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention
    Mejin, Melissa
    Tiong, Wen Ni
    Lai, Lana Yin Hui
    Tiong, Lee Len
    Bujang, Adam Mohamad
    Hwang, Siaw San
    Ong, Tiong Kiam
    Fong, Alan Yean Yip
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (04) : 621 - 628
  • [47] Induction of CYP2C19 and CYP3A Activity Following Repeated Administration of Efavirenz in Healthy Volunteers
    Michaud, V.
    Ogburn, E.
    Thong, N.
    Aregbe, A. O.
    Quigg, T. C.
    Flockhart, D. A.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (03) : 475 - 482
  • [48] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
    Chang‑Keun Cho
    Ji-Young Byeon
    Pureum Kang
    Hye-Jung Park
    Eunvin Ko
    Chou Yen Mu
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Archives of Pharmacal Research, 2023, 46 : 111 - 116
  • [49] A genetic polymorphism of CYP2C19 is associated with susceptibility to biliary tract cancer
    Isomura, Yoshihiro
    Yamaji, Yutaka
    Ohta, Miki
    Seto, Motoko
    Asaoka, Yoshinari
    Tanaka, Yasuo
    Sasaki, Takashi
    Nakai, Yousuke
    Sasahira, Naoki
    Isayama, Hiroyuki
    Tada, Minoru
    Yoshida, Haruhiko
    Kawabe, Takao
    Omata, Masao
    Koike, Kazuhiko
    JOURNAL OF GASTROENTEROLOGY, 2010, 45 (10) : 1045 - 1052
  • [50] PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes
    Chang-Keun Cho
    Eunvin Ko
    Ju Yeon Mo
    Pureum Kang
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Jung-Woo Bae
    Chang-Ik Choi
    Archives of Pharmacal Research, 2024, 47 (1) : 82 - 94